Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #99 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Wanbury Limited (this stock) | 697 | 11.5 | 26.6% | -20.0% | — | 44 | 65 | 25 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2025 | 163 | 14 | 13 | ₹ |
| March 31, 2025 | 172 | 19 | 20 | ₹ |
| Dec. 31, 2024 | 133 | 1 | 1 | ₹ |
| Sept. 30, 2024 | 161 | 8 | 8 | ₹ |
| June 30, 2024 | 131 | 1 | 1 | ₹ |
| March 31, 2024 | 139 | 34 | 34 | ₹ |
| Dec. 31, 2023 | 145 | 10 | 10 | ₹ |
| Sept. 30, 2023 | 144 | 7 | 7 | ₹ |
| June 30, 2023 | 146 | 5 | 5 | ₹ |
| March 31, 2023 | 133 | 1 | 1 | ₹ |
| Dec. 31, 2022 | 126 | -3 | -3 | ₹ |
| Sept. 30, 2022 | 124 | -1 | -1 | ₹ |
| June 30, 2022 | 117 | -7 | -7 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2025 | 600 | 30 | 31 |
| March 31, 2024 | 576 | 56 | 56 |
| March 31, 2023 | 500 | -10 | -10 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2025 | 26 | -51 | 26 | 49 | -23 |
| March 31, 2024 | 4 | -17 | 15 | 17 | -13 |
| March 31, 2023 | 20 | -9 | -32 | 0 | 20 |
| March 31, 2022 | 38 | 1 | -26 | 0 | 38 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2025 | 414 | 59 | 27 | 13 | 160 | 193 | 175 | 4 | 190 | 38 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
